Laura K. Shawver, PhD
Chief Executive Officer
Dr. Laura Shawver is chief executive officer of Cleave Biosciences focusing on the development of drugs against novel targets in protein homeostasis for difficult to treat cancers. She received her doctorate in pharmacology at the University of Iowa in 1984 and did postdoctoral training at the University of Virginia Cancer Center and the department of hematology and oncology at Washington University. Before joining Cleave, Shawver was CEO of Phenomix Corporation. Previously, she was president of SUGEN Inc. which focused on kinases and their function in cancer growth and survival. Her work in understanding the role of VEGF receptor in tumor angiogenesis led to the development of a new class of drugs including SutentTM currently marketed by Pfizer for kidney and stomach cancer. Prior to her employment at SUGEN Inc., Dr. Shawver was employed at Berlex Biosciences (formerly Triton Biosciences). Diagnosed with ovarian cancer in 2006, she founded the non-profit organization, The Clearity Foundation which provides access to molecular profiling for women with recurrent and refractory disease to help prioritize treatment options. Dr. Shawver is an active member in the American Association for Cancer Research currently serving on the Science Policy and Legislative Affairs Committee.